Dow Jones 30 Stocks SEC Filings — July 16, 2026

Raised full-year adjusted EPS guidance to $19.50-$20.00 (from prior range), implying ~15% YoY growth at the midpoint; earnings from operations surged 54% YoY to $8.0B, driven by margin recovery in Optum and UnitedHealthcare

Adjusted EPS of $6.38 in Q2 2026 grew 23% YoY from $5.17, significantly outpacing revenue growth of 0.4% YoY, indicating powerful operating leverage and cost controls

Optum Rx scripts declined 6.5% YoY to 387M (from 414M), and Optum Health patients served fell by ~700K, signaling competitive pressure and potential market share loss in pharmacy and care delivery

UnitedHealthcare membership dropped 525K sequentially, with Medicare Advantage losing 965K members since year-end 2025—a 4.5% decline in a key growth segment, likely due to rate cuts and plan exits

fairlife ransomware attack has temporarily suspended US production operations; while product quality is unaffected, the duration of the shutdown is unknown, creating near-term revenue risk for a high-growth dairy subsidiary

Four executives (Guggina, Dallaire, Milum, Watkins) collectively disposed of only ~852 shares via tax withholding (~$98K total), representing negligible insider selling—no bearish signal from management

EVP Woodford and Sr EVP Roeder exercised options and had shares withheld for taxes; net insider selling was minimal (~$104K combined), with holdings remaining substantial (61,523 and 2,981 shares respectively)—no conviction signal

Optum Insight completed the acquisition of Alegeus on July 2, 2026, expanding its health financial services platform; deal terms undisclosed but adds recurring revenue stream

Eliminated 33% of drug reauthorizations and 11% of pharmacy prior approvals for chronic conditions, a cost-saving initiative that could improve member satisfaction and reduce administrative expenses

Total UnitedHealthcare membership declined 525K sequentially, with Medicare Advantage losing 965K members since year-end 2025—a 4.5% decline in a high-margin segment, likely due to rate cuts and plan exits

Optum Rx scripts fell 6.5% YoY to 387M, and Optum Health patients served dropped by ~700K, suggesting competitive losses to CVS/Caremark and Cigna's Evernorth

fairlife ransomware attack has temporarily halted US production; the full scope and materiality are unknown, and recovery time is uncertain, posing a risk to Q3 2026 revenue and brand reputation

Q2 2026 revenue grew only 0.4% YoY to $112.0B, the slowest growth in recent quarters, as membership declines offset pricing gains—a warning sign for top-line momentum

The fairlife incident highlights concentration risk in a single high-growth subsidiary; any prolonged disruption could materially impact KO's overall growth narrative, as fairlife has been a key driver

EVP Woodford exercised 3,827 shares and Sr EVP Roeder exercised 3,115 shares, with only 1,069 total shares withheld for taxes; while not outright selling, the option exercises could precede future sales if stock price declines

The Louisiana market exit and Medicaid redeterminations caused a 380K membership loss in Community & State, a low-margin but stable revenue source, reducing diversification

Earnings from operations surged 54% YoY to $8.0B, and adjusted EPS grew 23% YoY, despite flat revenue—this operating leverage could drive further upside if membership stabilizes, making the stock attractive at current multiples

Full-year adjusted EPS guidance raised to $19.50-$20.00, implying H2 2026 acceleration; if membership attrition moderates, the company could beat the raised bar, creating a positive catalyst

The July 2 acquisition of Alegeus adds a health financial services platform (HSAs, FSAs, COBRA) to Optum Insight, providing a new recurring revenue stream and cross-sell opportunities with existing clients

The Gold Card program exempts high-performing providers from prior approval, covering ~10% of UHC's prior approval volume—this could reduce administrative costs and improve provider relations, a competitive advantage

If the ransomware incident is resolved quickly (days to weeks), fairlife's production could resume with minimal revenue impact; the stock may be oversold on the news, offering a tactical entry point for patient investors

The lack of any material insider selling (all tax-withholding disposals) across four executives suggests management sees no near-term risk, reinforcing confidence in WMT's defensive positioning and steady execution

The option exercises by two executives (Woodford and Roeder) indicate they are willing to invest in DIS stock, even after tax withholding; this could signal internal confidence in Disney's turnaround, especially with theme parks and streaming momentum

UnitedHealth Group's 54% YoY surge in operating earnings contrasts with membership declines (-525K) and script volume drops (-6.5% YoY), illustrating a sector-wide tension where cost-cutting and pricing power are offsetting volume losses. Investors should monitor whether this margin expansion is sustainable or a one-time benefit from prior-year reserve releases.

Coca-Cola's fairlife ransomware attack is the second major cybersecurity incident in the Dow 30 this quarter (after a similar event at a peer), highlighting that even blue-chip companies with strong brand equity are vulnerable to operational disruptions. This theme could pressure valuations across consumer staples if incidents become more frequent.

All six insider filings (Walmart and Disney) were routine tax-withholding transactions tied to option exercises or equity compensation, with no open-market purchases or sales. This pattern suggests that insider activity in large-cap Dow components is currently a low-signal indicator, unlike in small-caps where it often predicts moves.

UnitedHealth Group's upward revision to full-year EPS guidance (to $19.50-$20.00) stands out as a positive catalyst in a mixed earnings season, contrasting with the broader market's cautious tone. This could signal that healthcare services companies with pricing power are better positioned to navigate macro uncertainty.

Monitor for updates on the ransomware incident's resolution; any indication of prolonged downtime (beyond 2-3 weeks) could materially impact Q3 2026 revenue and trigger a sell-off. Next update likely via 8-K or earnings call in late July.

Watch for any stabilization in Medicare Advantage membership in Q3 2026; if attrition slows, the stock could re-rate higher given the strong margin performance. Next catalyst: Q3 2026 earnings in October.

Track monthly pharmacy script data from industry sources (e.g., IQVIA) to see if the 6.5% YoY decline in Optum Rx scripts accelerates or stabilizes; a further drop would confirm market share loss to competitors.

Although current filings are routine, any future open-market purchases by Walmart executives (especially CEO or CFO) would be a strong bullish signal; conversely, any sales beyond tax withholding would warrant attention.

The option exercises by Woodford and Roeder could precede future share sales; monitor Form 4 filings for any open-market disposals, which would indicate a lack of confidence in Disney's turnaround.

Watch for any disclosure of the ransomware's origin or data exfiltration; if customer data is compromised, legal and reputational risks could escalate, impacting KO's valuation.